Usefulness of FDG, MET and FLT-PET Studies for the Management of Human Gliomas

被引:33
作者
Miyake, Keisuke [1 ]
Shinomiya, Aya [1 ]
Okada, Masaki [1 ]
Hatakeyama, Tetsuhiro [1 ]
Kawai, Nobuyuki [1 ]
Tamiya, Takashi [1 ]
机构
[1] Kagawa Univ, Fac Med, Dept Neurol Surg, Miki, Kagawa 7610793, Japan
来源
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY | 2012年
关键词
POSITRON-EMISSION-TOMOGRAPHY; PRIMARY BRAIN-TUMORS; IMAGING PROLIFERATION; C-11-METHIONINE PET; DIAGNOSIS;
D O I
10.1155/2012/205818
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The use of positron imaging agents such as FDG, MET, and FLT is expected to lead the way for novel applications toward efficient malignancy grading and treatment of gliomas. In this study, the usefulness of FDG, MET and FLT-PET images was retrospectively reviewed by comparing their histopathological findings. FDG, MET, and FLT-PET were performed in 27 patients with WHO grade IV, 15 patients with WHO grade III, and 12 patients with WHO grade II during 5.5 years. The resulting PET images were compared by measuring SUVs and T/N ratios (tumor to normal tissue ratios). Although there were no significant differences in FDG-PET, there were significant differences in the T/N ratios in the MET-PET between WHO grades II and IV and in the FLT-PET between the WHO grades III and IV. In glioblastoma patients, the SUVs of the areas depicted by MRI in the MET-PET were different from those SUVs in the FLT-PET. Importantly, the areas with high SUVs in both MET-PET and FLT-PET were also high in Ki-67 index and were histologically highly malignant. PET imaging is a noninvasive modality that is useful in determining a tumor area for removal as well as improving preoperative diagnosis for gliomas.
引用
收藏
页数:11
相关论文
共 32 条
[1]  
[Anonymous], PROG COMPUT IMAGING
[2]  
Aronen HJ, 2000, CLIN CANCER RES, V6, P2189
[3]   [18F]FLT-PET in oncology:: current status and opportunities [J].
Been, LB ;
Suurmeijer, AJH ;
Cobben, DCP ;
Jager, PL ;
Hoekstra, HJ ;
Elsinga, PH .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (12) :1659-1672
[4]  
Ceyssens S, 2006, AM J NEURORADIOL, V27, P1432
[5]  
Chen W, 2005, J NUCL MED, V46, P945
[6]   Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography:: A pilot study [J].
Chen, Wei ;
Delaloye, Sibylle ;
Silverman, Daniel H. S. ;
Geist, Cheri ;
Czernin, Johannes ;
Sayre, James ;
Satyamurthy, Nagichettiar ;
Pope, Whitney ;
Lai, Albert ;
Phelps, Michael E. ;
Cloughesy, Timothy .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (30) :4714-4721
[7]   [18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors [J].
Choi, SJ ;
Kim, JS ;
Kim, JH ;
Oh, SJ ;
Lee, JG ;
Kim, CJ ;
Ra, YS ;
Yeo, JS ;
Ryu, JS ;
Moon, DH .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (06) :653-659
[8]   FDG-PET to predict different patterns of progression in multicentric glioblastoma: a case report [J].
Colavolpe, Cecile ;
Guedj, Eric ;
Metellus, Philippe ;
Barrie, Maryline ;
Figarella-Branger, Dominique ;
Mundler, Olivier ;
Chinot, Olivier .
JOURNAL OF NEURO-ONCOLOGY, 2008, 90 (01) :47-51
[9]   11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma [J].
Hatakeyama, Tetsuhiro ;
Kawai, Nobuyuki ;
Nishiyama, Yoshihiro ;
Yamamoto, Yuka ;
Sasakawa, Yasuhiro ;
Ichikawa, Tomotsugu ;
Tamiya, Takashi .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (11) :2009-2017
[10]   11C-methionine PET for differential diagnosis of low-grade gliomas [J].
Herholz, K ;
Hölzer, T ;
Bauer, B ;
Schröder, R ;
Voges, J ;
Ernestus, RI ;
Mendoza, G ;
Weber-Luxenburger, G ;
Löttgen, J ;
Thiel, A ;
Wienhard, K ;
Heiss, WD .
NEUROLOGY, 1998, 50 (05) :1316-1322